Collaboration will revolutionise treatment of diabetes
CPI is part of a European project titled ‘Nanofacturing’ which is focusing on the development and scale up of nanopharmaceutical production. Coordinated by Midatech Biogune, part of the UK based Midatech Pharma, this project will focus on the manufacture of insulin coated gold nanoparticles, that are being used in Midatech’s insulin delivery patch.
Develop the manufacturing process of insulin coated gold nanoparticles in order to allow non-invasive delivery of insulin to patients with diabetes.
The project utilised CPI’s capabilities in both biologics and formulation to support the manufacturing scale up of nanoparticle generation, insulin coating and final purification.
We are delighted to have joined forces with CPI on this project, they have provided a high level support and are an ideal partner going forward together with the other consortium members. Midatech is looking forward to a highly productive and fruitful collaboration which will form a key part of our portfolio development.
Dr Jim Phillips, CEO of Midatech
The delivery patch is a non-invasive, needle free, drug delivery mechanism which allows nanopharmaceuticals to be administered to the patient via a polymer strip which is applied inside the mouth. Initial uses for the treatment will be specific to patients suffering from diabetes but will also drive further development of treatment in areas such as oncology, central nervous system disorders and antivirals.
The project started in February 2015 and is expected to last 4 years. The intended outcome of the project is the successful design and build of a pilot and large scale manufacturing line for the production of nanopharmaceuticals. This project will utilise CPI’s capabilities in both biologics and formulation to support the manufacturing scale up of nanoparticle generation, insulin coating and final purification. The funding will also allow CPI to establish the infrastructure which other Nanopharmaceutical companies can access to support process development and scale up.
The project will leverage and enhance the expertise and knowledge of companies and academic centres of excellence across Europe that form the consortium, leaving a legacy that will support the further growth of this emerging high potential technology.
The consortium members are:
- Midatech Pharma Group
- Prochimia Surfaces
- Centre for BioNano Interactions, University College Dublin
- National University of Ireland
- Applus+ Laboratories
- IFOM, The FIRC Institute of Molecular Oncology
- Ecole Polytechnique Federale de Lausanne
Let’s innovate together
To find out more about how we can work together, please enter your details below.